{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:32:54Z","timestamp":1788863574878,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bone.2022.116613","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:39:38Z","timestamp":1668393578000},"page":"116613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model"],"prefix":"10.1016","volume":"167","author":[{"given":"Hirofumi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritaka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tokushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2022.116613_bb0005","first-page":"1201","article-title":"Regulation of parathyroid hormone secretion and pathogenesis of secondary hyperparathyroidism","volume":"56","author":"Komaba","year":"2014","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.bone.2022.116613_bb0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000325454","article-title":"Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality","volume":"32","author":"Brancaccio","year":"2011","journal-title":"Blood Purif."},{"key":"10.1016\/j.bone.2022.116613_bb0015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4158\/EP12141.RA","article-title":"Bone as an endocrine organ","volume":"18","author":"Guntur","year":"2012","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2022.116613_bb0020","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-021-01578-y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bone.2022.116613_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40268-022-00385-4","article-title":"First-in-human phase I study of the novel injectable calcimimetic agent upacicalcet in healthy adult Japanese participants","volume":"22","author":"Koiwa","year":"2022","journal-title":"Drugs R&D"},{"key":"10.1016\/j.bone.2022.116613_bb0030","series-title":"Presented at: Kidney Week 2020 Reimagined, TH-OR","article-title":"Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a phase 3 study","volume":"20","author":"Akizawa","year":"2020"},{"key":"10.1016\/j.bone.2022.116613_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2369-15-69","article-title":"Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5\/6 nephrectomy and adenine models","volume":"15","author":"Ferrari","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bone.2022.116613_bb0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nefro.2015.08.004","article-title":"Animal models of pediatric chronic kidney disease. Is adenine intake an appropriate model?","volume":"35","author":"Claramunt","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.bone.2022.116613_bb0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.afos.2021.11.001","article-title":"Analysis of bone in adenine-induced chronic kidney disease model rats","volume":"7","author":"Saito","year":"2021","journal-title":"Osteoporos. Sarcopenia"},{"key":"10.1016\/j.bone.2022.116613_bb0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1681\/ASN.20203110S1148b","article-title":"Upacicalcet, a novel non-peptide calcimimetic for the treatment of secondary hyperparathyroidism, has a low risk of hypocalcemia [abstract no. PO0318]","volume":"31","author":"Nishimura","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2022.116613_bb0055","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.3748\/wjg.v11.i29.4505","article-title":"Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats","volume":"11","author":"Shichijo","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bone.2022.116613_bb0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF03346610","article-title":"Effect of intermittent treatment with human parathyroid hormone 1\u201334 in SAMP6 senescence-accelerated mice","volume":"33","author":"Washimi","year":"2010","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2022.116613_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.bone.2022.116613_bb0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.bone.2022.116613_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/sdi.12734","article-title":"Treatment of secondary hyperparathyroidism: how do cinacalcet and etelcalcetide differ?","volume":"31","author":"Eidman","year":"2018","journal-title":"Semin. Dial."},{"key":"10.1016\/j.bone.2022.116613_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13180","article-title":"Adenine-induced chronic kidney disease in rats","volume":"23","author":"Diwan","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.bone.2022.116613_bb0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2022.116613_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232428","article-title":"Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism","volume":"15","author":"Sakai","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bone.2022.116613_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116613_bb0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.21037\/atm.2019.06.44","article-title":"Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats","volume":"7","author":"Ni","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bone.2022.116613_bb0105","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40266-019-00696-3","article-title":"Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly","volume":"36","author":"Galassi","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bone.2022.116613_bb0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","article-title":"Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism","volume":"67","author":"Colloton","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2022.116613_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115963","article-title":"Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels","volume":"148","author":"Metzger","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116613_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1538\/expanim1978.28.1_1","article-title":"Maturation process of secondary ossification centers in the rat and assessment of bone age","volume":"28","author":"Fukuoka","year":"1979","journal-title":"Exp. Anim."},{"key":"10.1016\/j.bone.2022.116613_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5935\/0101-2800.20130024","article-title":"Vascular calcification in chronic kidney disease: a review","volume":"35","author":"de Oliveira","year":"2013","journal-title":"J. Bras. Nefrol."},{"key":"10.1016\/j.bone.2022.116613_bb0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2022.116613_bb0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00198-019-05187-0","article-title":"The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormoneOsteoporos","volume":"31","author":"Jansz","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2022.116613_bb0140","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.3390\/ijms21228712","article-title":"Therapeutic effect of calcimimetics on osteoclast-osteoblast crosslink in chronic kidney disease and mineral bone disease","volume":"21","author":"Hung","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2022.116613_bb0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.kint.2018.12.015","article-title":"Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration","volume":"95","author":"D\u00edaz-Tocados","year":"2019","journal-title":"Kidney Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:44:28Z","timestamp":1762659868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222002903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":29,"alternative-id":["S8756328222002903"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116613","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116613"}}